Harmony Biosciences Holdings, Inc. (HRMY)

HRMY Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	158.69	145.49	128.85	181.47	34.6
Depreciation & Amortization	25.34	24.11	24.36	23.39	18.84
Stock-Based Compensation	44.9	42.6	31.71	26.17	15.66
Other Adjustments	27.47	14.94	-0.57	-82.46	28.83
Change in Receivables	-13.75	-8.89	-19.4	-19.9	-12.67
Changes in Inventories	1.84	-1.84	-1.07	0.14	-0.61
Changes in Accounts Payable	3.95	-5.38	8.95	2.79	-1.56
Changes in Accrued Expenses	-	-	-	-	17.26
Changes in Other Operating Activities	99.78	8.79	46.55	12.87	-1.8
Operating Cash Flow	348.2	219.82	219.39	144.47	98.56
Operating Cash Flow Growth	58.40%	0.20%	51.86%	46.58%	-
Capital Expenditures	-0.31	-1.15	-0.31	-0.17	-0.3
Purchases of Investments	-86.15	-105.29	-127.47	-110.73	-
Proceeds from Sale of Investments	81.06	98.53	118.31	9.07	-
Payments for Business Acquisitions	-	-33.07	-36.97	-	-
Other Investing Activities	-34.25	-26.5	-	-40	-100
Investing Cash Flow	-39.65	-67.48	-46.44	-141.83	-100.3
Long-Term Debt Issued	-	-	200	-	200
Long-Term Debt Repaid	-16.25	-15	-201.25	-2	-200.5
Net Long-Term Debt Issued (Repaid)	-16.25	-15	-1.25	-2	-0.5
Issuance of Common Stock	10.21	6.5	5.06	8.84	39.37
Repurchase of Common Stock	-	-	-100	-	-
Net Common Stock Issued (Repurchased)	10.21	6.5	-94.95	8.84	39.37
Other Financing Activities	-3	-2.5	-9.36	-	-30.45
Financing Cash Flow	-9.05	-11	-105.55	6.84	7.42
Net Cash Flow	299.5	141.34	67.4	9.48	5.68
Free Cash Flow	347.89	218.67	219.08	144.29	98.26
Free Cash Flow Growth	59.09%	-0.19%	51.82%	46.85%	-
FCF Margin	40.06%	30.59%	37.64%	32.95%	32.17%
Free Cash Flow Per Share	5.94	3.78	3.63	2.36	1.66
Levered Free Cash Flow	273.03	155.02	206.09	218.47	65.94
Unlevered Free Cash Flow	284.42	169.28	221.18	247.34	112.75

Updated Feb 24, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q